Compare Moderna, Inc. (MRNA) vs VanEck Rare Earth/Strategic Metals (REMX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Moderna, Inc. vs VanEck Rare Earth/Strategic Metals — how do they compare? Moderna, Inc. trades at $225 (market cap $78.65B), while VanEck Rare Earth/Strategic Metals trades at $60.97 (market cap $1.75B). The key difference: Moderna, Inc. is far larger — about 44.9× VanEck Rare Earth/Strategic Metals's market cap, and Moderna, Inc. is trading nearer its 52-week high, VanEck Rare Earth/Strategic Metals nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Moderna, Inc. for 59 Days and VanEck Rare Earth/Strategic Metals for 50 Days on average.
| MRNA | REMX | |
|---|---|---|
Market Cap | $78.65B | $1.75B |
Volume | 37,373,437 | 930,523 |
Sector | Health | Sector/Thematic |
52-Week High | $203.46 | $109.53 |
52-Week Low | $22.36 | $60.58 |
Typical Hold Time | 59 Days | 50 Days |
Enterprise Value | $74.80B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Moderna (MRNA) trades at $197.00, up 0.26% on the day, with technical indicators showing a bullish trend and strong momentum. The stock has rallied over 500% in 2026, driven by positive clinical updates for its cancer vaccine pipeline and inclusion in the Nasdaq-100 index effective October 9, 2026. However, fundamentals remain challenging with revenue declining from $18.9B in 2022 to $1.9B in 2025 and negative net income margins exceeding 140%.
While technical momentum and pipeline optimism support near-term upside, valuation appears stretched with P/S of 35.08 and negative profitability metrics. Key risks include execution on non-COVID products, competitive pressure, and sustainability of recent gains. Analyst consensus is cautious with only 28% buy ratings and $115.70 price target suggesting significant downside from current levels.
REMX (VanEck Rare Earth and Strategic Metals ETF) trades at $60.97, down 1.47% with a bearish technical outlook. The ETF faces selling pressure across moving averages and oscillators, though RSI readings below 14 suggest potential oversold conditions. Recent news highlights strategic importance of rare earth metals amid U.S. efforts to reduce dependence on China, with Bank of America increasing its stake by 72.1% in the latest quarter.
The ETF offers exposure to 38 global rare earth companies but carries high volatility (~50% annualized) and significant China exposure. While geopolitical trends support long-term demand, current technical weakness and sector-specific risks warrant caution. The reshoring trade provides structural tailwinds, but investors should be prepared for elevated price swings.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Moderna, Inc.
Moderna, Inc. operates as a clinical stage biotechnology company. The Company focuses on the discovery and development of messenger RNA (mRNA) therapeutics and vaccines. Moderna develops mRNA medicines for infectious, immuno-oncology, and cardiovascular diseases.
Read more on MRNA →About VanEck Rare Earth/Strategic Metals
REMX invests in global companies involved in producing, refining, and recycling rare earth and strategic metals. It provides targeted exposure to critical minerals used in high-tech and green energy, with top holdings like Albemarle and Pilbara Minerals.
Read more on REMX →
